A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

Overview

About this study

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in participants with advanced malignancies.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Capable of giving signed informed consent, which includes compliance with the
requirements and restrictions listed in the informed consent form (ICF) and in this
protocol.

- Male or female participants ≥ 18 years of age (or age ≥ regionally approved age of
consent for participation in investigational clinical studies) at the time of signing
the informed consent.

- Contraceptive use by men and women should be consistent with local regulations
regarding the methods of contraception for those participating in clinical studies.

- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

- Adequate organ and marrow function

Exclusion Criteria:

- History of trauma or major surgery within 28 days prior to the first dose of study
treatment.

- Prior treatment with an anti-TIGIT antibody.

- Any active or prior autoimmune disease that required treatment within 3 years of the
first dose of study treatment.

- Prior chemotherapy, targeted small-molecule therapy, immunotherapy, or biologic
agents, or use of other investigational drugs within 28 days before first dose of
study treatment.

- Discontinued prior immunotherapy for immune related adverse events with a high
severity.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 12/15/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Thanh Ho, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

Jacksonville, Fla.

Mayo Clinic principal investigator

Jason Starr, D.O.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Mahesh Seetharam, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

More information

Publications

Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions